Skip to main content
Top
Published in: Clinical and Experimental Nephrology 5/2015

01-10-2015 | Original Article

Novel urinary biomarkers in pre-diabetic nephropathy

Authors: Vikas Garg, Manish Kumar, Himansu Sekhar Mahapatra, Anubhuti Chitkara, Adesh Kumar Gadpayle, Venketansan Sekhar

Published in: Clinical and Experimental Nephrology | Issue 5/2015

Login to get access

Abstract

Background

Renal involvement was thought to occur more than 10 years after onset of diabetes, but recent studies provide evidence that it starts even in the pre-diabetes stage. However, there is no sensitive marker to detect these changes at such early stages. Novel urinary biomarkers have showed promising results in detection of early nephropathy in pre-diabetics.

Methods

A total of 91 subjects (diabetes 61 and pre-diabetes 30) were enrolled into the study. Urinary biomarkers such as urine Neutrophil Gelatinase-Associated Lipocalin (NGAL), urine Cystatin C and urine albumin–creatinine ratio (UACR) were estimated. Subjects were further divided in four groups on the basis of UACR: pre-diabetes with normoalbuminuria (21); pre-diabetes with microalbuminuria (9); diabetes with normoalbuminuria (37); and diabetes with microalbuminuria (24). The relationship of UACR, NGAL, and Cystatin C was estimated.

Results

Urine levels of NGAL and Cystatin C were significantly higher in microalbuminuria group compared to normoalbuminuria. UACR was positively correlated to urine NGAL–creatinine ratio (UNCR) and urine Cystatin C–creatinine ratio (UCCR) in both diabetes and pre-diabetes. On logistic regression odds ratio of UNCR to predict microalbuminuria in diabetes and pre-diabetes was 1.070 (p = 0.000) and 1.138 (p = 0.010), respectively. Area under curve was determined by ROC analysis, and UNCR was found to be better than UCCR for estimating microalbuminuria.

Conclusion

Tubular damage may play major role in development of nephropathy in pre-diabetes. Newer markers like urine NGAL and Cystatin C are raised early in diabetes and pre-diabetes nephropathy.
Literature
1.
go back to reference American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37:s81–90.CrossRef American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37:s81–90.CrossRef
2.
go back to reference Thomas MC, Burns WC, Cooper ME. Tubular changes in early diabetic nephropathy. Adv Chronic Kidney Dis. 2005;12:177–86.CrossRefPubMed Thomas MC, Burns WC, Cooper ME. Tubular changes in early diabetic nephropathy. Adv Chronic Kidney Dis. 2005;12:177–86.CrossRefPubMed
3.
go back to reference Comper WD, Hilliard LM, Nikolic-Paterson DJ, Russo LM. Disease dependent mechanism of albuminuria. Am J Physiol Renal Physiol. 2008;295:F1589–600.CrossRefPubMed Comper WD, Hilliard LM, Nikolic-Paterson DJ, Russo LM. Disease dependent mechanism of albuminuria. Am J Physiol Renal Physiol. 2008;295:F1589–600.CrossRefPubMed
4.
go back to reference Krolewski AS, Niewczas MA, Skupien J, et al. Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria. Diabetes Care. 2014;37:226–34.PubMedCentralCrossRefPubMed Krolewski AS, Niewczas MA, Skupien J, et al. Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria. Diabetes Care. 2014;37:226–34.PubMedCentralCrossRefPubMed
5.
go back to reference Molitch ME, Steffes M, Sun W, Epidemiology of Diabetes Interventions and Complications Study Group, et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care. 2010;33:1536–43.PubMedCentralCrossRefPubMed Molitch ME, Steffes M, Sun W, Epidemiology of Diabetes Interventions and Complications Study Group, et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care. 2010;33:1536–43.PubMedCentralCrossRefPubMed
6.
go back to reference Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA. 2003;289:3273–7.CrossRefPubMed Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA. 2003;289:3273–7.CrossRefPubMed
7.
go back to reference National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis. 2012;60:850–86.CrossRef National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis. 2012;60:850–86.CrossRef
9.
go back to reference Jeon YK, Kim MR, Huh JE, Mok JY, et al. Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes. J Korean Med Sci. 2011;26:258–63.PubMedCentralCrossRefPubMed Jeon YK, Kim MR, Huh JE, Mok JY, et al. Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes. J Korean Med Sci. 2011;26:258–63.PubMedCentralCrossRefPubMed
10.
go back to reference Nielsen SE, Schjoedt KJ, Astrup AS, Tarnow L, et al. Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril. Diabet Med. 2010;27(10):1144–50.CrossRefPubMed Nielsen SE, Schjoedt KJ, Astrup AS, Tarnow L, et al. Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril. Diabet Med. 2010;27(10):1144–50.CrossRefPubMed
11.
go back to reference Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002;40:221–6.CrossRefPubMed Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002;40:221–6.CrossRefPubMed
12.
go back to reference Filler G, Bokenkamp A, Hofmann W, Le Bricon T, et al. Cystatin C as a marker of GFR -history, indications, and future research. Clin Biochem. 2005;38:1–8.CrossRefPubMed Filler G, Bokenkamp A, Hofmann W, Le Bricon T, et al. Cystatin C as a marker of GFR -history, indications, and future research. Clin Biochem. 2005;38:1–8.CrossRefPubMed
13.
go back to reference Yang J, Mori K, Li JY, Barasch J. Iron, lipocalin, and kidney epithelia. Am J Physiol Renal Physiol. 2003;285:F9–18.CrossRefPubMed Yang J, Mori K, Li JY, Barasch J. Iron, lipocalin, and kidney epithelia. Am J Physiol Renal Physiol. 2003;285:F9–18.CrossRefPubMed
14.
go back to reference Mishra J, Ma Q, Prada A, Mitsnefes M, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol. 2003;14:2534–43.CrossRefPubMed Mishra J, Ma Q, Prada A, Mitsnefes M, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol. 2003;14:2534–43.CrossRefPubMed
15.
go back to reference Mishra J, Mori K, Ma Q, Kelly C, Barasch J, Devarajan P. Neutrophil gelatinase associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol. 2004;24:307–15.CrossRefPubMed Mishra J, Mori K, Ma Q, Kelly C, Barasch J, Devarajan P. Neutrophil gelatinase associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol. 2004;24:307–15.CrossRefPubMed
16.
go back to reference Mishra J, Dent C, Tarabishi R, Mitsnefes MM, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet. 2005;365:1231–8.CrossRefPubMed Mishra J, Dent C, Tarabishi R, Mitsnefes MM, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet. 2005;365:1231–8.CrossRefPubMed
17.
go back to reference Kim SS, Song SH, Kim IJ, Jeon YK, et al. Urinary Cystatin C and Tubular proteinuria predict progression of diabetic nephropathy. Diabetes Care. 2013;36:656–61.PubMedCentralCrossRefPubMed Kim SS, Song SH, Kim IJ, Jeon YK, et al. Urinary Cystatin C and Tubular proteinuria predict progression of diabetic nephropathy. Diabetes Care. 2013;36:656–61.PubMedCentralCrossRefPubMed
18.
19.
go back to reference Wu J, Ding Y, Zhu C, Shao X, et al. Urinary TNF-α and NGAL are correlated with the progression of nephropathy in patients with type 2 diabetes. Exp Ther Med. 2013;6:1482–8.PubMedCentralPubMed Wu J, Ding Y, Zhu C, Shao X, et al. Urinary TNF-α and NGAL are correlated with the progression of nephropathy in patients with type 2 diabetes. Exp Ther Med. 2013;6:1482–8.PubMedCentralPubMed
20.
go back to reference Fu WJ, Li BL, Wang SB, Chen ML, et al. Changes of the tubular markers in type 2 diabetes mellitus with glomerular hyperfiltration. Diabetes Res Clin Pract. 2012;95(1):105–9.CrossRefPubMed Fu WJ, Li BL, Wang SB, Chen ML, et al. Changes of the tubular markers in type 2 diabetes mellitus with glomerular hyperfiltration. Diabetes Res Clin Pract. 2012;95(1):105–9.CrossRefPubMed
21.
go back to reference Holman RR, Paul SK, Bethel MA, Matthews DR, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.CrossRefPubMed Holman RR, Paul SK, Bethel MA, Matthews DR, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.CrossRefPubMed
22.
go back to reference Remuzzi G, Macia M, Ruggenenti P. Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study. J Am Soc Nephrol. 2006;17(S2):S90–7.CrossRefPubMed Remuzzi G, Macia M, Ruggenenti P. Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study. J Am Soc Nephrol. 2006;17(S2):S90–7.CrossRefPubMed
23.
go back to reference Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253–9.CrossRef Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253–9.CrossRef
24.
go back to reference Borgman JM, Skorecki K. Chronic kidney disease. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL,editors. Harrison’s principles of internal medicine. 18th ed. New York: McGraw-Hill; 2012. p. 2308–2321. Borgman JM, Skorecki K. Chronic kidney disease. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL,editors. Harrison’s principles of internal medicine. 18th ed. New York: McGraw-Hill; 2012. p. 2308–2321.
25.
go back to reference Levey AS, Bosch JP, Lewis JB, Green T, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–70.CrossRefPubMed Levey AS, Bosch JP, Lewis JB, Green T, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–70.CrossRefPubMed
26.
go back to reference Tapp RJ, Shaw JE, Zimmet PZ, Balkau B, et al. Albuminuria is evident in the early stages of diabetes onset: results from the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Am J Kidney Dis. 2004;44(5):792–8.CrossRefPubMed Tapp RJ, Shaw JE, Zimmet PZ, Balkau B, et al. Albuminuria is evident in the early stages of diabetes onset: results from the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Am J Kidney Dis. 2004;44(5):792–8.CrossRefPubMed
27.
go back to reference Tarsio JF, Reger LA, Furcht LT. Molecular mechanisms in basement membrane complications of diabetes. Alterations in heparin, laminin, and type IV collagen association. Diabetes. 1988;37(5):532–9.CrossRefPubMed Tarsio JF, Reger LA, Furcht LT. Molecular mechanisms in basement membrane complications of diabetes. Alterations in heparin, laminin, and type IV collagen association. Diabetes. 1988;37(5):532–9.CrossRefPubMed
28.
go back to reference Duncan ER, Walker SJ, Ezzat VA, Wheatcroft SB, et al. Accelerated endothelial dysfunction in mild prediabetic insulin resistance: the early role of reactive oxygen species. Am J Physiol Endocrinol Metab. 2007;293:E1311–9.CrossRefPubMed Duncan ER, Walker SJ, Ezzat VA, Wheatcroft SB, et al. Accelerated endothelial dysfunction in mild prediabetic insulin resistance: the early role of reactive oxygen species. Am J Physiol Endocrinol Metab. 2007;293:E1311–9.CrossRefPubMed
29.
go back to reference Makris K, Nikolaki E, Nanopoulos K, Pirqakis KM, et al. Measurement of Cystatin C in human urine by particle enhanced turbidimetric immunoassay on automated biochemistry analyzer. Clin Biochem. 2013;46(12):1128–30.CrossRefPubMed Makris K, Nikolaki E, Nanopoulos K, Pirqakis KM, et al. Measurement of Cystatin C in human urine by particle enhanced turbidimetric immunoassay on automated biochemistry analyzer. Clin Biochem. 2013;46(12):1128–30.CrossRefPubMed
30.
go back to reference Conti M, Moutereau S, Zater M, Lallali K, et al. Urinary Cystatin C as a specific marker of tubular dysfunction. Clin Chem Lab Med. 2006;44(3):288–91.CrossRefPubMed Conti M, Moutereau S, Zater M, Lallali K, et al. Urinary Cystatin C as a specific marker of tubular dysfunction. Clin Chem Lab Med. 2006;44(3):288–91.CrossRefPubMed
31.
go back to reference Woo KS, Choi JL, Kim BR, Kim JE, et al. Urinary neutrophil gelatinase-associated lipocalin levels in comparison with glomerular filtration rate for evaluation of renal function in patients with diabetic chronic kidney disease. Diabetes Metab J. 2012;36:307–13.PubMedCentralCrossRefPubMed Woo KS, Choi JL, Kim BR, Kim JE, et al. Urinary neutrophil gelatinase-associated lipocalin levels in comparison with glomerular filtration rate for evaluation of renal function in patients with diabetic chronic kidney disease. Diabetes Metab J. 2012;36:307–13.PubMedCentralCrossRefPubMed
32.
go back to reference Lacquaniti A, Donato V, Pintaudi B, Vieste GD, et al. ‘‘Normoalbuminuric’’ diabetic nephropathy: tubular damage and NGAL. Acta Diabetol. 2013;50:935–42.CrossRefPubMed Lacquaniti A, Donato V, Pintaudi B, Vieste GD, et al. ‘‘Normoalbuminuric’’ diabetic nephropathy: tubular damage and NGAL. Acta Diabetol. 2013;50:935–42.CrossRefPubMed
33.
go back to reference Assal HS, Tawfeek S, Rasheed EA, Lebedy DE, et al. Serum cystatin C and tubular urinary enzymes as biomarkers of renal dysfunction in type 2 diabetes mellitus. Clin Med Insights Endocrinol Diab. 2013;6:7–13. Assal HS, Tawfeek S, Rasheed EA, Lebedy DE, et al. Serum cystatin C and tubular urinary enzymes as biomarkers of renal dysfunction in type 2 diabetes mellitus. Clin Med Insights Endocrinol Diab. 2013;6:7–13.
34.
go back to reference Fu WJ, Xiong SL, Fang YG, Wen S, et al. Urinary tubular biomarkers in short-term type 2 diabetes mellitus patients: a cross-sectional study. Endocrine. 2012;41(1):82–8.CrossRefPubMed Fu WJ, Xiong SL, Fang YG, Wen S, et al. Urinary tubular biomarkers in short-term type 2 diabetes mellitus patients: a cross-sectional study. Endocrine. 2012;41(1):82–8.CrossRefPubMed
35.
go back to reference Mori K, Lee HT, Rapoport D, Drexler IR, et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest. 2005;115(3):610–21.PubMedCentralCrossRefPubMed Mori K, Lee HT, Rapoport D, Drexler IR, et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest. 2005;115(3):610–21.PubMedCentralCrossRefPubMed
36.
go back to reference Kaseda R, Iino N, Hosojima M, Takeda T, et al. Megalin-mediated endocytosis of cystatin C in proximal tubule cells. Biochem Biophys Res Commun. 2007;357(4):1130–4.CrossRefPubMed Kaseda R, Iino N, Hosojima M, Takeda T, et al. Megalin-mediated endocytosis of cystatin C in proximal tubule cells. Biochem Biophys Res Commun. 2007;357(4):1130–4.CrossRefPubMed
37.
go back to reference Vaidya VS, Waikar SS, Ferguson MA, et al. Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans. Clin Transl Sci. 2008;1(3):200–8.PubMedCentralCrossRefPubMed Vaidya VS, Waikar SS, Ferguson MA, et al. Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans. Clin Transl Sci. 2008;1(3):200–8.PubMedCentralCrossRefPubMed
38.
go back to reference Russo LM, Sandoval RM, Campos SB, et al. Impaired tubular uptake explains albuminuria in early diabetic nephropathy. J Am Soc Nephrol. 2006;17:2937–44.CrossRef Russo LM, Sandoval RM, Campos SB, et al. Impaired tubular uptake explains albuminuria in early diabetic nephropathy. J Am Soc Nephrol. 2006;17:2937–44.CrossRef
Metadata
Title
Novel urinary biomarkers in pre-diabetic nephropathy
Authors
Vikas Garg
Manish Kumar
Himansu Sekhar Mahapatra
Anubhuti Chitkara
Adesh Kumar Gadpayle
Venketansan Sekhar
Publication date
01-10-2015
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 5/2015
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-015-1085-3

Other articles of this Issue 5/2015

Clinical and Experimental Nephrology 5/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.